- Report
- August 2023
- 110 Pages
Global
From €4539EUR$4,750USD£3,862GBP
- Report
- February 2024
- 70 Pages
North America
From €4539EUR$4,750USD£3,862GBP
- Report
- March 2024
- 184 Pages
Global
From €3224EUR$3,374USD£2,744GBP
€3583EUR$3,749USD£3,048GBP
- Report
- March 2024
- 198 Pages
Global
From €3224EUR$3,374USD£2,744GBP
€3583EUR$3,749USD£3,048GBP
- Report
- July 2023
- 220 Pages
Global
From €1902EUR$1,990USD£1,618GBP
- Report
- May 2024
- 140 Pages
Global
From €6211EUR$6,499USD£5,284GBP
From €6212EUR$6,500USD£5,285GBP
- Report
- February 2024
- 150 Pages
Global
From €4539EUR$4,750USD£3,862GBP
- Report
- August 2023
- 110 Pages
Global
From €4539EUR$4,750USD£3,862GBP
- Report
- August 2023
- 80 Pages
Global
From €4539EUR$4,750USD£3,862GBP
- Clinical Trials
- April 2024
- 200 Pages
Global
From €4778EUR$5,000USD£4,066GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1195EUR$1,250USD£1,016GBP
- Report
- January 2024
- 200 Pages
Global
From €3966EUR$4,150USD£3,374GBP
- Report
- February 2024
- 70 Pages
United States
From €4539EUR$4,750USD£3,862GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4539EUR$4,750USD£3,862GBP
- Report
- February 2024
- 100 Pages
Asia Pacific
From €4539EUR$4,750USD£3,862GBP
- Report
- February 2024
- 80 Pages
Europe
From €4539EUR$4,750USD£3,862GBP
- Report
- February 2024
- 80 Pages
North America
From €4539EUR$4,750USD£3,862GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4539EUR$4,750USD£3,862GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4539EUR$4,750USD£3,862GBP
Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more